Communications

Advertising Communications Graphic Design Internet Marketing Media Publishing SEO
News Release Digital Asset Direct

NOA Lithium Strikes Critical Water: A Game-Changing Discovery for Rio Grande Project

Global Markets News

In the parched landscapes of Argentina's Lithium Triangle, water is as valuable as the lithium itself. NOA Lithium Brines Inc. (TSXV: NOAL) (OTCPK: NLIBF) has just announced a discovery that could dramatically accelerate the development timeline of its flagship Rio Grande Project—fresh water. The company revealed today that it has successfully located an on-site fresh water source within its 100%-owned Rio Grande Project boundaries, marking a pivotal milestone in the project's advancement toward production. Why This Water Discovery Matters For lithium brine projects, access to industrial water is a make-or-break factor. In the arid regions where lithium salars are typically found, securing water rights and sources can be challenging, expensive, and time-consuming. By discovering this resource on its own property, NOA has eliminated a significant hurdle in the development pathway. "This marks another significant milestone in the advancement of the Rio Grande Project," stated Gabriel Rubacha, NOA's Chief Executive Officer. "Not only have we discovered a fresh water source on-site and within our properties, but its location aligns perfectly with the area of highest lithium concentration and our preliminary assessment for locating a production facility and evaporation ponds." The strategic positioning of this water well, drilled to a depth of 190 meters in the northern section of the project, couldn't be more advantageous. It's situated close to the areas where NOA has identified the highest concentration of lithium and porosity to date—precisely where the company envisions developing future production facilities and evaporation ponds. A Series of Strategic Wins This water discovery adds to NOA's impressive streak of achievements over the past year. The company has methodically checked off critical boxes in its development roadmap: The water well represents one of three fresh water targets identified at Rio Grande, suggesting further potential for expanded water resources as development continues. Positioned in the Heart of the Lithium Triangle NOA's strategic position in Argentina's Lithium Triangle gives it proximity to some of the world's highest-grade, lowest-cost lithium operations. The company has assembled one of the largest lithium brine claim portfolios in the region not owned by a producing company, with over 140,000 hectares across three prospective salars: Rio Grande, Arizaro, and Salinas Grandes. This vast land package in Salta Province—widely recognized as one of Argentina's most mining-friendly jurisdictions—positions NOA alongside industry leaders like Arcadium, Lithium Argentina, Ganfeng, and Rio Tinto. Looking Forward: Accelerating Development With the PEA expected in Q3 2025, NOA is rapidly advancing toward a comprehensive economic evaluation of the Rio Grande Project. The current design contemplates an initial production capacity of approximately 20,000 metric tonnes per year of lithium carbonate equivalent, with scalability to double that capacity through modular expansion. The water discovery adds tangible value to this economic assessment by potentially reducing both capital and operating costs associated with water procurement and transport. As global lithium demand continues to surge, driven by electric vehicle adoption and energy storage requirements, NOA's steady advancement of its Rio Grande Project positions it as an emerging player in the lithium supply chain at precisely the right time. For investors watching the lithium space, NOA's methodical derisking of its flagship project and continued achievement of development milestones make it a compelling story to follow as it progresses toward its goal of becoming Argentina's next major lithium producer. ‎ Recent News Highlights from NOA Lithium: NOA Lithium Discovers Fresh Water at Rio Grande Project NOA Engages Hatch To Lead Preliminary Economic Assessment For Its Rio Grande Project NOA Lithium Advances Towards 2025 Water Exploration at Rio Grande Project Read more about other lithium stocks: NASDAQ: PWM | OTC: LTMCF | NYSE: ALB | NYSE: LAC | OTCQB:NRVTF * Legal Disclaimer & Disclosure - Paid Advertisement: This content is a paid advertisement. Wall Street Wire has received compensation from NOA Lithium Brines Inc. for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available here redditwire.com/terms or in NOA's disclosure's THIS ARTICLE CONTAINS SPONSORED CONTENT PUBLISHED ON BEHALF OF NOA LITHIUM BRINES Contact Details ‎ media.globalmarkets@gmail.com

June 24, 2025 09:18 AM Eastern Daylight Time

News Release

DarioHealth's Platform Solves GLP-1's Biggest Problem, New Research Shows, While Trading at 1% of Hinge Health's $3 Billion Valuation

Global Markets News

DarioHealth Corp. (NASDAQ: DRIO), a digital health innovator in the chronic condition management space, just unveiled significant research findings at the American Diabetes Association Scientific Sessions that could dramatically improve its position in the $100 billion weight loss market. The company's studies demonstrate sustainable outcomes for GLP-1 users even after discontinuing medication - addressing a critical challenge in the industry. The latest findings revealed dramatic improvements in GLP-1 users, with average blood glucose levels dropping from an estimated A1c of 9.0% to 6.7%. Most importantly, users who discontinued GLP-1 medication maintained stable outcomes with no significant weight or glucose rebound for at least six months, according to the company's research. The company's platform leverages artificial intelligence to deliver personalized interventions, with its AI predictive models achieving 89% accuracy in forecasting future glucose levels. These capabilities position DarioHealth to support the growing demand for effective GLP-1 management solutions. Valuation Gap Creates Opportunity With DRIO shares currently trading around $0.69 and a market cap of approximately $30 million, the company appears dramatically undervalued compared to digital health peers. Hinge Health (NYSE: HNGE), which focuses primarily on musculoskeletal care, recently completed its IPO in May 2025 and now trades with a market cap of over $3 billion. This valuation disparity highlights the potential upside for DarioHealth investors. Unlike Hinge Health's focus on musculoskeletal care, DarioHealth offers a multi-condition platform addressing diabetes, hypertension, weight management, and behavioral health. This broader approach provides more comprehensive value to health plans and employers seeking to consolidate digital health vendors. DarioHealth has made strategic moves to strengthen its market position: The company expanded its GLP-1 capabilities through a partnership with MediOrbis, adding prescribing capabilities to enhance its weight management solution It's targeting both employer markets and direct-to-consumer channels The company has built its client base to 97 organizations with a reported 90%+ renewal rate The latest research validates DarioHealth's approach to sustainable weight management. With 44% of large employers now covering obesity drugs according to a Mercer survey, the demand for supportive digital health tools continues to grow. The Financial Picture DarioHealth has been making progress toward improved financial performance. In Q1 2025, the company reported revenue of $6.75 million, a 17% year-over-year increase, with gross margins of 57.5% (70.5% on a non-GAAP basis). Operating expenses decreased 35% compared to the previous year, as the company works toward its stated goal of operational cash flow breakeven by the end of 2025. The Bottom Line As GLP-1 medications continue to reshape weight management approaches, DarioHealth's platform offers a solution to maintain outcomes beyond medication use. The company's comprehensive condition management approach contrasts with more narrowly focused digital health providers like Hinge Health. For investors interested in the digital health sector, DarioHealth may represent an opportunity at current price levels, though it carries the execution risks typical of smaller healthcare technology companies. The significant valuation gap between DarioHealth's $30 million market cap and Hinge Health's $3 billion valuation highlights the potential upside if the company continues to execute on its strategy and build on its latest research findings. ‎ Recent News from Dario: Dario Unveils Groundbreaking GLP-1 and AI-Personalization Digital Health Findings DarioHealth Reports First Quarter 2025 Financial and Operating Results Dario's Digital Health Solution Demonstrates Effectiveness in New Research Examining Flu Vaccination Awareness in High-Risk Populations DarioHealth to Report First Quarter 2025 Results on Wednesday, May 14, 2025 DarioHealth Closes Strategic Refinancing of Existing Debt Facility of up to $50 Million to Provide Additional Operational Flexibility and Support Growth Initiatives ‎ Important Legal Disclaimer & Disclosur e - Paid Advertisement: This content is a paid advertisement. Wall Street Wire has received compensation from DarioHealth Corp. for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available redditwire.com/terms. Contact Details ‎ media.globalmarkets@gmail.com

June 24, 2025 09:07 AM Eastern Daylight Time

News Release

The $4.1 Trillion Healthcare Revolution: How DarioHealth Could Rewrite the Rules of Chronic Disease Management

Global Markets News

Imagine a world where managing multiple chronic conditions isn’t a nightmare of fragmented care, endless appointments, and mounting medical bills. This isn’t a futuristic fantasy, it’s the vision of DarioHealth Corp. (NASDAQ: DRIO)*, a digital health company that’s quietly building what could be the most comprehensive solution to America’s chronic disease crisis. The numbers are staggering. Chronic diseases consume a mind-boggling 90% of the $4.1 trillion U.S. healthcare budget, according to the CDC. Worse, 42% of Americans juggle multiple chronic conditions, with 12% managing five or more. It’s a system broken beyond repair, or so it seemed. Enter DarioHealth, a digital health innovator that’s reimagining healthcare from the ground up. Unlike traditional point solutions that tackle one condition at a time, this company has developed an AI-powered platform that simultaneously addresses diabetes, hypertension, weight management, musculoskeletal pain, and mental health. The company’s journey is as compelling as its technology. Born from years of user interaction data spanning 150,000 consumers, DarioHealth has built more than just an app, it’s created an intelligent ecosystem that learns and adapts to individual health journeys. Their AI-driven platform isn’t just tracking metrics; it’s predicting and preventing health complications before they escalate. But this isn’t just another tech pipe dream. The company’s approach is delivering real-world results that are turning heads across the healthcare industry. Imagine reducing hyperglycemic events by 58%, cutting anxiety symptoms by 59%, and delivering a 5x return on investment for healthcare payers. These aren’t marketing promises, they’re proven outcomes. The GLP-1 weight loss revolution provides a perfect window into DarioHealth’s strategic brilliance. With the weight loss medication market set to explode to $100 billion by 2030, the company has positioned itself as more than just a support platform. Through a strategic partnership with MediOrbis, they now offer integrated medication prescribing, solving the critical problem that sees 75% of patients discontinuing GLP-1 medications within a year. 2025 has been a breakthrough year. The company has added 14 new clients, bringing their total to 97 organizations. More importantly, over 80% of new contracts now cover multiple health conditions, a clear validation of their holistic approach. Major players like Blue Cross Blue Shield are taking notice, and the company’s client renewal rate sits at an impressive 90%. Financially, the story is equally compelling. First-quarter 2025 revenues hit $6.75 million, a 17% year-over-year growth. But the real magic is happening behind the scenes. The company is deploying AI to streamline operations, with a laser focus on reaching operational cash flow breakeven by the end of 2025 or early 2026. Recent industry comparisons, like the recent IPO of Omada Health (NASDAQ: OMDA) at much higher multiples, highlight the potential undervaluation of DarioHealth’s innovative platform. For investors tired of overhyped tech promises, DarioHealth may offer something different. Trading at around $0.69 with a market cap of ~$30 million, this could be the definition of a hidden gem. The company isn’t just building a product, it’s reimagining how chronic disease management could work in the digital age. Consider the market opportunity. With 129 million Americans suffering from at least one major chronic disease, and healthcare costs continuing to spiral, DarioHealth sits at the intersection of a massive market need and technological innovation. Recent analyst reports have even suggested the stock could reach $3, a potential 335% upside from current levels. This isn’t just another digital health play. This is a potential blueprint for the future of healthcare, personalized, integrated, and powered by intelligent technology. In a world where healthcare complexity continues to grow, DarioHealth represents a beacon of hope, promising not just management, but meaningful transformation of how we approach chronic health. ‎ ‎ Recent News Highlights from Dario DarioHealth Reports First Quarter 2025 Financial and Operating Results Dario's Digital Health Solution Demonstrates Effectiveness in New Research Examining Flu Vaccination Awareness in High-Risk Populations DarioHealth to Report First Quarter 2025 Results on Wednesday, May 14, 2025 DarioHealth Closes Strategic Refinancing of Existing Debt Facility of up to $50 Million to Provide Additional Operational Flexibility and Support Growth Initiatives - * Legal Disclaimer & Disclosure - Paid Advertisement: This content is a paid advertisement. Wall Street Wire has received compensation from DarioHealth Corp. for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available redditwire.com/terms. Contact Details ‎ media.globalmarkets@gmail.com

June 23, 2025 10:54 AM Eastern Daylight Time

Inspira Technologies Receives $2 Price Target and Buy Rating: Everything You Need to Know

Global Markets News

Litchfield Hills Research has initiated coverage of Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN)* with a Buy rating and a $2 price target, representing potential upside of over 225% from current trading levels of around $0.61 per share. This bullish outlook comes as the medical technology company continues to critical care technology addressing what the analyst describes as "a medical need without good options." The analyst notes that mechanical ventilators are "WWII technology in desperate need of an upgrade" with reports showing that 30% to 50% of ICU patients don't survive. Unlike mechanical ventilation, Inspira's ART500 technology would enable patients to remain awake during treatment while stabilizing oxygen levels without intubation and coma. What distinguishes Inspira from typical early-stage medical device companies is its proven regulatory execution and early commercial success. The company's first generation technology, the INSPIRA ART100 system, received FDA clearance in May 2024 and is already deployed in leading U.S. hospitals. The excitement around this technology reached a new high in April 2025 when the first successful patient treatment was completed at Westchester Medical Center. The commercial momentum seems to be accelerating. Inspira announced it received payment in the "low hundreds of thousands of dollars" from its U.S. distributor for delivered systems, marking the company's first revenues. CEO Dagi Ben-Noon called this "a transformative milestone for Inspira as we establish our presence in the U.S. medical landscape." The company has now initiated global commercial rollout discussions and expects additional deliveries in the second half of 2025. Central to Inspira's technology platform is the AI-powered HYLA blood sensor, which recently achieved 96% accuracy in clinical studies at Sheba Medical Center, one of the world's top hospitals. The system provides continuous monitoring without requiring blood draws, targeting the blood gas analyzer market projected to reach $5.7 billion by 2030. The analyst identifies massive market opportunities, with the global mechanical ventilators market expected to reach $20.69 billion by 2034. Inspira's flagship INSPIRA ART500 system in development aims to disrupt this market by providing respiratory support through direct blood oxygenation rather than forcing air into damaged lungs. Inspira has established strong intellectual property protection with multiple U.S. patents and novel patent claims protecting its core technologies. The company is executing a strategic approach of securing FDA clearance for individual components before integrating them into comprehensive systems. When comparing Inspira to similar medical device companies, the analyst found the stock trades at significant discounts despite having FDA-cleared technology already treating patients. The $2 price target reflects confidence in the company's ability to capitalize on its early commercial success and expand into the massive mechanical ventilation market. The analyst concludes that Inspira may represents a unique opportunity, combining proven FDA-cleared technology with substantial market opportunity and attractive valuation metrics in the high-growth medical device sector. Recent News from Inspira: Inspira Technologies Initiates Global Commercial Rollout of FDA-Cleared ART100 System INSPIRA ART100 System Approved by Israel's Largest Healthcare Provider for Use in Organ Transplant Patients Inspira Achieves above 99% Gas Exchange Efficiency in VORTX™ Technology In-Vivo Animal Testing * Legal Disclaimer & Disclosure: Nothing in this article constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published by the Wall Street Wire platform & media network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This article contains paid promotional content related to Inspira Technologies and was produced as part of their paid subscription to Wall Street Wire, which includes a monthly fee of five thousand US dollars paid in cash via bank transfer in return for promotional content and distribution services. The operators also receive additional fees for non promotional advisory and data services. Inspira Technologies did not necessarily review or approve this content prior to publication. Please review the full disclaimers and compensation disclosures here which include further details: redditwire.com/terms. We are not responsible for third party analyst price targets or market estimates are refer to them based on publicly availble reports. Additional or competing price target may exist and readers are advised to refer to the full report and its respective disclaimers and disclosures. Contact Details Wall Street Wire Editorial Desk media.globalmarkets@gmail.com

June 02, 2025 09:19 AM Eastern Daylight Time

Finding Ferdinand Shatters Sales Projections Following Debut Retail Launch at Credo Beauty

Finding Ferdinand

Finding Ferdinand, the sister-run brand on a mission to elevate your everyday routine with vegan, skin-loving formulas, is shattering sales projections just two months into the brand’s retail debut with Credo Beauty. In March 2025, the clean beauty brand launched online on credobeauty.com and rolled out to 14 Credo Beauty stores nationwide. Finding Ferdinand has far exceeded expectations since launching at Credo Beauty. Within just two months of the retail launch, the brand surpassed sales forecasts by an impressive triple digits. Additionally, Finding Ferdinand’s viral black lip balm was one of the top selling products during the Friends of Credo sale. Credo Beauty’s Senior Color Merchant, Meghan Lim, praised the brand as “Best in Class” for its exceptional launch performance at the retailer. “It’s been incredibly exciting to see Finding Ferdinand on shelves at Credo Beauty — a huge milestone for us. We’re absolutely ecstatic about the success so far, and this is just the beginning. Credo Beauty has been such a thoughtful and supportive partner, truly aligned with our values. Together, we’re keeping the momentum going by creating thoughtful in-store events and developing products and colors we know our customers will use and love,” said Nhu Le, Founder of Finding Ferdinand. Founded in 2015 by Nhu Le and now run alongside her sister, My Le, Finding Ferdinand celebrates its 10-year anniversary this year, marking a decade of innovation in color cosmetics. Nhu and My’s inspiration for the brand came from the incredible women in their family, especially their mother, a two-time cancer survivor whose strength continues to inspire the brand’s deep commitment to clean formulas. Finding Ferdinand products are 100% vegan and cruelty-free, offering proprietary cosmetic formulations that are clean and non-toxic. Finding Ferdinand takes to heart being a part of creating a better future for the world, and is committed to keeping the brand’s production sustainable - from working in small batches to prioritizing recyclable, recycled, or refillable components. For more information, follow the brand on Instagram @findingferdinand and TikTok @findingferdinand. ABOUT FINDING FERDINAND Effortless Beauty for Every Moment. Sister-run beauty brand Finding Ferdinand is here to elevate your everyday routine with vegan, skin-loving formulas that enhance—not hide—what makes you, you. Our clean, high-performance beauty essentials are designed for the way you live: easy to wear, impossible to mess up, and always a perfect fit. We hope you find something you love—and wear it your way, every day. ABOUT CREDO BEAUTY Credo Beauty offers today’s largest clean and sustainably minded beauty assortment in North America, across color, skincare, haircare and fragrance, partnering with over 135 leading brands, such as Westman Atelier, ILIA, OSEA, True Botanicals, Necessaire, and ROZ. Having built the most comprehensive guidelines, “The Credo Clean Standard™", customers can trust that they are purchasing the most effective, innovative products with safer ingredients with an emphasis on sustainable, natural and ethical materials. Trained makeup artists and estheticians (who are continually being educated by Credo Beauty and our brands) offer an exceptional experience both in-store and online. Visit one of the 15 brick-and-mortar store locations or www.credobeauty.com. MEDIA CONTACT Hallie Sawyer hsawyer@ogakidigital.com Contact Details Hallie Sawyer +1 818-388-7338 hsawyer@ogakidigital.com Company Website https://www.findingferdinand.com/

May 21, 2025 04:00 PM Eastern Daylight Time

Sardius Media Powers Gather25

Digifora

Sardius Media was founded in 2014 and is headquartered in Kansas City, Missouri. It exists to make mission-driven broadcasting and online event planning easier and more engaging. This is done through its first-in-class media platform as well as elite support from its experienced team of veteran software engineers and event specialists. Learn more at sardius.media. Sardius Media Powers Gather25 Sardius Media helped broadcast Gather25 for a non-stop 25-hour marathon on March 1, 2025. In that time, seven million Christians tuned in from around the globe. The event marked the debut and first full-scale test of Sardius Media’s AWS Elemental Anywhere, which amplified the reach of the event to 225 countries, providing live streaming and real-time AI and human interpretation in 87 different languages. The Global Impact of Gather25 Gather25 made history as an unprecedented 25-hour global broadcast uniting millions of Christians in prayer, worship, repentance, and commissioning. The broadcast streamed live sessions from seven locations in the United States, New Zealand, Malaysia, Romania, Rwanda, the United Kingdom, and Peru. This reached an audience of over 3.1 million unique users and over 21,000 self-organized gatherings (with a potential group reach of over seven million). These included a Dzaleka refugee camp in Malawi and 5,000 individuals gathered outdoors in Cebu City, Philippines. Notably, 117,000 U.S. prison inmates participated through the PandoApp from God Behind Bars. Amy Bay, Executive Director of Gather25, said, “What we saw at Gather25 was a picture of heaven — believers from every nation, tribe, and language coming together with one mission: to make Jesus known. We are so grateful to the Sardius team for the broadcast technology to pull it all together; it wouldn’t have happened without them.” Jonathan Sheehan (Future City Now, Renewed Vision), the producer of the event, said, "For decades, I’ve been producing large-scale events, and by any measure, Gather25 was a monumental undertaking. The sheer scope of the event, paired with the complexity of the technological challenges, demanded more than just vendors—we needed true partners. That’s exactly what we found in the Sardius team. Their skilled professionals dove into the trenches with us, collaborating tirelessly to bring this vision to life. The resulting millions who joined the event is a testament to a great partnership.” Architecting a Historical Broadcast Sardius Media was presented with a complex challenge to deliver a seamless broadcast delivery experience to this large global audience. In addition, they had to support real-time translation of AI and human interpretation in 87 different languages with a wide array of delivery options, including live interpreters, AI closed captions, voice interpretation, and core broadcast streams. Encoding numerous concurrent streams for such a long broadcast was a unique challenge, as well. The Sardius Team came together with event partner Future City Now to develop a global design aesthetic for the event. This incorporated complex workflows to seamlessly deliver the right content to the right audience in real time. Sardius Media accomplished this by leveraging AWS’s new Elemental MediaLive Anywhere product for its first large-scale deployment. They collaborated closely with the AWS team to ensure flawless performance and maintained this even when the popular Bible App YouVersion notified 36 million users to join the event, leading to a robust response. The AWS-powered streaming infrastructure managed the complexities without skipping a beat, delivering a resilient, scalable live stream for more than a full day and carrying the hope-filled message of Gather25 to every corner of the earth. Overcoming Unexpected Challenges With Agility and Innovation One challenge from Gather25 demonstrated the Sardius Media team’s agility in implementing its solutions and adapting to real-time barriers. Less than 24 hours before the event, the main fiber circuit into the studio master control was severed by an unexpected car accident. Sardius Media swiftly coordinated with various partners, secured alternate internet solutions, and rerouted encoder traffic. This ensured the stream was ready on time. Other unexpected challenges arose during the live stream, but each was efficiently addressed by the experienced Sardius team. Jason Shore, co-founder of Sardius Media, reflected on the milestone achievement, saying, “Gather25 pushed the boundaries of what’s possible in live streaming. Our team’s ability to adapt, innovate, and deliver under pressure made this a defining moment — not just for us, but for the global Church.” Gather25 showcased Sardius Media’s leadership in live streaming for mission-driven events — and this is just the beginning. Upcoming product updates and their continued AWS partnership promise even more innovation for future gatherings. About Sardius Media Sardius Media was founded in 2014 and is headquartered in Kansas City, Missouri. It exists to make mission-driven broadcasting and online event planning easier and more engaging. This is done through its first-in-class media platform as well as elite support from its experienced team of veteran software engineers and event specialists. Learn more at sardius.media. Transform your marketing efforts with strategies that yield results, build trust, and provide peace of mind. From strategic planning to implementation, digifora is your trusted partner, acting as an extension of your team or even becoming your dedicated marketing department if needed. Contact Details digifora Justin Brackett +1 843-284-6594 digifora.co@gmail.com Company Website https://digifora.com

May 01, 2025 12:48 PM Eastern Daylight Time

Image

News Release

Market Alert: Buy Rating Reiterated for Actelis Networks with $5 Price Target

Actelis Networks, Inc.

Litchfield Hills Research analyst Theodore O'Neill has reiterated his Buy rating and $5 price target on Actelis Networks (Nasdaq: ASNS)* following the company's recent financial results. The analyst emphasizes that when viewed on a rolling four-quarter basis, Actelis' business is "moving in the right direction – up and to the right." The report highlights that Actelis shares are "priced significantly below peer averages," trading at a discount of 85% to 93% on sales measures compared to industry peers. O'Neill notes that if Actelis were to trade at the simple average of its peers at 3.67x 2026 Market cap/sales, the share price would exceed $6.00, above his current $5 target. For the full year 2024, Actelis reported revenue of ~$7.8 million, representing a 38% increase compared to FY2023. The company achieved a substantial improvement in gross margin to ~55% from ~34% in the prior year, demonstrating the effectiveness of its strategic shift toward IoT sales and higher-margin software components. Operating expenses decreased by ~13% year-over-year, reflecting the company's continued cost reduction initiatives while maintaining focus on its core markets including Federal, Military, and Smart City/Transportation sectors. Click here if you'd like to receive more alerts from us Recent Actelis Networks News Highlights: Actelis Networks to Report Annual 2024 Financial Results on Monday, March 24, 2025 Actelis Networks Reports Full Year 2024 Results: Revenue Sees 38% Growth Reaching $7.8 Million, 125% Increase in Gross Margin, Loss Per Share Shrinks by 67% to $0.85 Actelis Networks Secures Order for Countywide Intersection Modernization in Ventura County, California *DISCLAIMER: This alert is published by Wall Street Wire. Wall Street Wire does not provide financial or investment advice, and our content does not represent an offer to buy or sell securities. Wall Street Wire is a promotional content brand and its operators are not registered brokers, dealers, or investment advisers. This alert contains and is a form of paid promotional content for to Actelis Networks and was produced as part of their paid subscription to Wall Street Wire’s distribution and promotional content services. This alert has not been reviewed or approved by Actelis Networks prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms Contact Details WALL STREET WIRE Market Alerts Desk media.globalmarkets@gmail.com

March 27, 2025 12:33 PM Eastern Daylight Time

Monster Energy Continues the Launch of Java Monster Irish Crème Flavor In Spectacular Fashion at Chicago’s St. Patrick’s Day Celebrations

YourUpdateTV

In a city renowned for its spirited St. Patrick's Day celebration, Monster Energy is going all out to ensure the continued launch of Java Monster Irish Crème is as memorable as the legendary patron saint himself. The Chicago River will gleam a brilliant emerald green, mirroring the lively spirit of the day, thanks to Monster Energy's participation in the annual river-dyeing tradition. Monster Energy, the brand synonymous with exhilarating energy drinks, is continuing its innovation and celebration to the next level. In an unforgettable display of excitement and flavor, Monster Energy is proudly introducing its latest creation, the Java Monster Irish Crème, amidst the vibrant festivities of Chicago's St. Patrick's Day parade. The streets of Chicago will be alive with the roar of the Java Monster truck, a behemoth of energy making its way through the parade. Decked out in striking Monster Energy branding and the bold, irresistible allure of the Java Monster Irish Crème flavor, the truck will be a sight to behold. Adding to the day's excitement, the Monster Energy team, alongside the enchanting Monster Girls and a particularly mischievous leprechaun, will traverse the parade route. gifting thousands of eager parade-goers with cans of the Java Monster Irish Crème. This creamy, dreamy addition to the Java Monster lineup is infused with the rich, smooth taste of Irish crème, promising an invigorating energy boost with every sip. About Java Monster: No foam, extra hot, half-caf, no-whip, soy latte… enough of the coffeehouse BS already. It’s time to get out of the line and step up to what’s next. Java Monster, premium coffee and cream, brewed up with killer flavor, supercharged with the Monster Energy blend. Coffee done the monster way, wide open, with a take no prisoners attitude and the experience and know-how to back it up. Flavors include Mean Bean, Loca Moca, Salted Caramel, Irish Creme, Caffe Latte, and Triple Shot (Mocha and French Vanilla). So, shake gently and unleash the beast within. Java Monster – anything but basic! About Monster Energy: Based in Corona, California, Monster Energy is the leading marketer of energy drinks and alternative beverages. Refusing to acknowledge the traditional, Monster Energy supports the scene. Whether motocross, off-road, NASCAR, MMA, BMX, surf, snowboard, ski, skateboard, eSports or the rock and roll lifestyle, Monster Energy is a brand that believes in authenticity and the core of what its sports, athletes, gamers and musicians represent. More than a drink, it's the way of life lived by athletes, bands, believers, and fans. See more about Monster Energy including all of its drinks at www.monsterenergy.com. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

March 19, 2025 11:15 AM Eastern Daylight Time

Video

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug

Global Markets News

NeuroSense's Groundbreaking ALS Combination Therapy PrimeC Advances Towards commercialization in Canada potential for revenue in canada alone of $100-150 million dollars. PrimeC Has Previously Demonstrated Unprecedentedly Strong Clinical Efficacy; Market News Alerts Reports -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN)* has announced significant progress toward the early commercialization of PrimeC in Canada. According to a Form 6-K filed with the SEC this morning, Health Canada has invited the company to a pre-New Drug Submission (pre-NDS) meeting to discuss a potential Notice of Compliance/conditional (NOC/c) regulatory pathway for PrimeC as a treatment for Amyotrophic Lateral Sclerosis (ALS). NeuroSense is targeting potential approval in Canada by H1 2026. The company estimates peak annual revenue potential of $100-150M USD in the Canadian market. This meeting marks a critical step in NeuroSense's regulatory strategy for PrimeC PrimeC is NeuroSense's lead drug candidate for ALS, a novel extended-release oral formulation combining ciprofloxacin and celecoxib. The drug has demonstrated promising results in clinical trials, including the Phase 2b PARADIGM study, which showed a 36% reduction in disease progression and 43% improvement in survival rates compared to placebo. In December 2024, NeuroSense reported positive FDA feedback on its Phase 3 trial design for PrimeC, with plans to initiate the pivotal study in mid-2025. The company has also announced entering a binding term sheet with a global pharmaceutical company to advance PrimeC's development, which includes substantial upfront payments and funding for the Phase 3 program. This Canadian regulatory development represents a potential pathway to earlier commercialization while the larger Phase 3 program proceeds for global markets. The neurodegenerative disease treatment market has witnessed transformative licensing deals that highlight the immense value of innovative therapies. GlaxoSmithKline's 2021 collaboration with Alector set a remarkable precedent with a $700 million upfront payment and potential milestone payments of $1.5 billion, while the Biogen and Denali Therapeutics partnership in 2020 involved $560 million upfront and potential milestones approaching $1.125 billion. These deals underscore the pharmaceutical industry's willingness to invest heavily in breakthrough neurological innovations, potentially like NeuroSense's PrimeC. Some Wall Street Analysts reportedly maintain a Buy Rating for NeuroSense with AGP giving the company a $7.50 price target representing a significant premium over current Prices; * Disclaimer: Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This alert is published by Market News Alerts, a promotional content brand which is part of the Wall Street Wire™ network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This distribution is paid promotional content related to NeuroSense Therapeutics and was produced as part of their paid subscription to Wall Street Wire. This report has not been reviewed or approved by NeuroSense Therapeutics prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms. We are not responsible for the price targets mentioned in this article nor do we it endorse them, they are quoted based on publicly available news reports and additional or price targets may exist that may not have been quoted. Readers are advised to refer to the full reports mentioned on various systems and the disclaimers/disclosures they may be subject to. Contact Details Market News Alerts Editorial Desk globalmarkets.media@gmail.com

March 19, 2025 11:01 AM Eastern Daylight Time

1 2 3 4 5 ... 42